# **SAFETY DATA SHEETS**

# This SDS packet was issued with item:

078949201

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078920213

## Safety Data Sheet



#### Section 1: Identification

**Product identifier** 

**Product Name** 

**Product Code** 

Latanoprost Ophthalmic Solution, 0.005%

AB46304; Core No. 463; NDC 24208-0463-25

Relevant identified uses of the substance or mixture and uses advised against

Recommended use

 Finshed Pharmaceutical Product; Latanoprost Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Restrictions on use

 Refer to the product insert and/or prescribing information for restrictions on use and contraindications.

## Details of the supplier of the safety data sheet

Manufacturer

Bausch & Lomb

1400 North Goodman Street

Rochester, NY 14609

United States bausch.com

Telephone (General) • 1-800-553-5340

**Emergency telephone number** 

Manufacturer • 1-800-535-5053 - Infotrac

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to consumer use of the product.

#### Section 2: Hazard Identification

#### **UN GHS**

According to: UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

#### Classification of the substance or mixture

**UN GHS** • Acute Toxicity Oral 5

Label elements

Preparation Date: 06/May/2015

**UN GHS** 

WARNING

Hazard statements • May be harmful if swallowed

**Precautionary statements** 

**Prevention** • Use only in accordance with label instructions and supplied prescibing information. Wash thoroughly after handling.

Response • IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

If eye irritation persists: Get medical advice/attention.

Revision Date: 06/May/2015

Format: GHS Language: English (US)
UN GHS

IF ON SKIN: Wash with plenty of soap and water.

If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician.

Storage/Disposal • Protect from light. Store unopened bottle(s) under refrigeration at 2° to 8°C (36°to 46°F). During shipment to the patient, the bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 8 days. Once a bottle is opened for use, it may be stored at room temperature up to 25°C (77°F) for 6 weeks. Dispose of content and/or container in accordance with local, regional, national, and/or international regulations.

Other hazards

**UN GHS** 

No data available

## Section 3 - Composition/Information on Ingredients

#### **Substances**

Material does not meet the criteria of a substance according to United Nations Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

#### **Mixtures**

| Composition                |  |         |  |
|----------------------------|--|---------|--|
| Chemical Name              | Identifiers                            | %       | Classifications According to Regulation/Directive                              |
| Benzalkonium Chloride      | CAS:63449-41-2<br>EINECS:264-151-<br>6 | 0.02%   | UN GHS: Skin Corr. 1B; Acute Tox. Oral 4; Acute Tox. Dermal 4; Aquatic Acute 1 |
| Dibasic Sodium Phosphate   | CAS:7558-80-7<br>EINECS:231-449-<br>2  | < 1%    | UN GHS: NDA  |
| Latanoprost                | CAS:130209-82-4                        | 0.005%  | UN GHS: NDA  |
| Monobasic Sodium Phosphate | CAS:10049-21-5                         | < 1%    | UN GHS: NDA  |
| Sodium chloride            | CAS:7647-14-5<br>EINECS:231-598-<br>3  | < 1%    | UN GHS: Skin Irrit. 2; Eye Irrit. 2A; Acute Tox. Oral 5                        |
| Water                      | CAS:7732-18-5<br>EINECS:231-791-<br>2  | Balance | UN GHS: Classification criteria not met  |

The exact percentage of composition has been withheld as a trade secret.

#### Section 4: First-Aid Measures

#### **Description of first aid measures**

Inhalation

• Remove to fresh air. If signs/symptoms develop, get medical attention.

Skin

IF ON SKIN: Wash with plenty of soap and water. If skin irritation occurs: Get medical advice/attention.

Eye

For accidental and non-therapeutic applications, flush eyes with copious amounts of water for at least 15 minutes. Get medical attention. If eye irritation persists: Get medical advice/attention.

#### Ingestion

Preparation Date: 06/May/2015

Revision Date: 06/May/2015

If swallowed, rinse mouth with water (only if the person is conscious) Call a physician

Format: GHS Language: English (US)

or poison control center immediately. Individuals who have ingested the drug should be monitored for symptoms associated with exposure to beta-adreneric blocking agents, as described in the supplemental information provided in Section 2 (Hazard Identification), including repiratory, cardiac, or cardiopulmonary reactions.

## Most important symptoms and effects, both acute and delayed

 Refer to the product insert and/or product prescribing information for comprehensive information regarding adverse reactions and other important symptoms and effects.

## Indication of any immediate medical attention and special treatment needed

## Section 5: Fire-Fighting Measures

## Extinguishing media

Suitable Extinguishing Media . Water spray, carbon dioxide, dry chemical powder or appropriate foam for surrounding

Unsuitable Extinguishing Media

No data available

None known.

**Firefighting Procedures** 

Fire fighters should wear complete protective clothing including self-contained breathing apparatus.

#### Special hazards arising from the substance or mixture

Unusual Fire and Explosion

Hazards

**Hazardous Combustion Products** 

During a fire, thermal decomposition or combustion may generate irritating and highly toxic gases.

#### Advice for firefighters

No data available

#### Section 6 - Accidental Release Measures

# Personal precautions, protective equipment and emergency procedures

**Personal Precautions** 

 No special controls or personal protection required under conditions of intended use. In the event of bulk spills, wear suitable protective eyewear, clothing, protective boots and protective gloves. Evacuate immediate area. Ensure adequate ventilation. Refer to Section 8. No special precautions expected to be necessary if material is used under ordinary conditions and as recommended. Avoid any skin contact.

**Emergency Procedures** 

 No emergency procedures are expected to be necessary when used in accordance with product literature.

#### **Environmental precautions**

No data available on the environmental impact of this product.

## Methods and material for containment and cleaning up

Containment/Clean-up Measures

Use appropriate Personal Protective Equipment (PPE) Wash away spilled liquid remainder with plenty of water. For bulk material spills: Contain spilled product. For small spills, add suitable absorbent material. Scoop up and place in an appropriate liquid-tight container equipped with a tight cover for disposal. For large spills, dike spilled material or otherwise contain material to ensure runoff does not reach a waterway. Place spilled material in an appropriate, liquid-tight container equipped with a tight cover for disposal.

#### Reference to other sections

Refer to Section 8 - Exposure Controls/Personal Protection and Section 13 - Disposal Considerations.

## Section 7 - Handling and Storage

Preparation Date: 06/May/2015 Format: GHS Language: English (US) UN GHS Revision Date: 06/May/2015 Page 3 of 10

## Precautions for safe handling

Handling

 Use only in accordance with product literature. Wash thoroughly with warm water and soap after handling.

## Conditions for safe storage, including any incompatibilities

Storage

 Protect from light. Store unopened bottle(s) under refrigeration at 2° to 8°C (36°to 46°F). During shipment to the patient, the bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 8 days. Once a bottle is opened for use, it may be stored at room temperature up to 25°C (77°F) for 6 weeks.

Special Packaging Materials • Maintain product in original container only.

## Section 8 - Exposure Controls/Personal Protection

#### Control parameters

**Exposure Limits/Guidelines** 

Refer to the occupational exposure limits / guidelines for the individual product components.

#### Exposure controls

Engineering Measures/Controls

No special controls are required under conditions of intended use. Local exhaust ventilation should be provided when handling bulk product.

**Personal Protective Equipment Pictograms** 





Respiratory

No special controls or personal protection required under conditions of intended use. In the event of a bulk spill, a NIOSH-certified air-purifying respirator equipped with HEPA -organic vapor cartridges may be permissible under certain circumstances where airborne concentrations are expected to exceed exposure limits and when adequate oxygen is present. Use a positive pressure air-supplied respirator if there is any potential for an uncontrolled release or any other circumstances where air purifying respirators may not provide adequate protection.

Eye/Face

 No special personal protection required under conditions of intended use. In the event of a bulk spill, appropriate eye protection should be worn.

Hands

No special personal protection required under conditions of intended use. In the event of a bulk spill, wear rubber or nitrile gloves.

Skin/Body

No special personal protection required under conditions of intended use. In the event of a bulk spill, wear appropriate protective clothing.

Thermal hazards

None known.

General Industrial Hygiene Considerations

**Environmental Exposure** Controls

Avoid contact with skin and eyes. Wash thoroughly with soap and water after handling.

No special controls are required under conditions of intended use. In the event of a bulk spill, prevent spilled material from entering storm sewers or drains, waterways, and contact with the soil.

# Section 9 - Physical and Chemical Properties

# Information on Physical and Chemical Properties

| Material Description                          |          |                |                               |  |
|---|----------|----------------|-------------------------------|--|
| Physical Form                                 | Liquid   | Color          | Colorless to slightly yellow. |  |
| Odor  | No odor. | Odor Threshold | Not relevant                  |  |
| Physical and Chemical Properties Not relevant |          |                |                               |  |
| General Properties                            |          |                |                               |  |

Preparation Date: 06/May/2015 Revision Date: 06/May/2015

Page 4 of 10 Obtained by Global Safety Management, 1-813-435-5161 - www.GSMSDS.com

| Boiling Point                       | No data available | Melting Point        | Not relevant |  |  |
|-------------------------------------|-------------------|----------------------|--------------|--|--|
| Decomposition Temperature           | No data available | рН                   | 6.7          |  |  |
| Specific Gravity/Relative Density   | = 1.0073          | Bulk Density         | Not relevant |  |  |
| Water Solubility                    | Soluble           | Solvent Solubility   | Not relevant |  |  |
| Viscosity                           | No data available | Explosive Properties | Not relevant |  |  |
| Volatility                          |                   |                      |              |  |  |
| Vapor Pressure                      | Not relevant      | Vapor Density        | Not relevant |  |  |
| Evaporation Rate                    | No data available | Volatiles (Wt.)      | Not relevant |  |  |
| Flammability                        |                   |                      |              |  |  |
| Flash Point                         | Not relevant      | UEL                  | Not relevant |  |  |
| LEL                                 | Not relevant      | Autoignition         | Not relevant |  |  |
| Environmental                       |                   |                      |              |  |  |
| Octanol/Water Partition coefficient | No data available |                      |              |  |  |
|                                     |                   |                      |              |  |  |

## **Section 10: Stability and Reactivity**

## Reactivity

Stable under normal temperatures and pressures.

## **Chemical stability**

No data available

## Possibility of hazardous reactions

No data available

#### Conditions to avoid

Extreme heat or cold. Do not freeze. Protect from light.

## Incompatible materials

Consult physician regarding potential drug interactions.

## Hazardous decomposition products

 During a fire, thermal decomposition or combustion may generate irritating and highly toxic gases.

# **Section 11 - Toxicological Information**

## Information on toxicological effects

Other Material Information

 Toxicological information refers to raw materials only. Concentrations and toxicological effects are substantially reduced in the product.

| Components                      |                 |   |  |
|---------------------------------|-----------------|---|--|
| Latanoprost (0.005%)            | 130209-82-<br>4 | Acute Toxicity: Intravenous-Rat LD50 • >2 mg/kg   |  |
| Benzalkonium Chloride (0.02%)   |                 | Acute Toxicity: Ingestion/Oral-Mouse LD50 • 150 mg/kg; <i>Behavioral</i> :Somnolence (general depressed activity); <i>Blood</i> :Hemorrhage |  |
| Sodium chloride (< 1%)          | 7647-14-5       | Acute Toxicity: Ingestion/Oral-Rat LD50 • 3000 mg/kg  |  |
| Dibasic Sodium Phosphate (< 1%) | 7558-80-7       | Acute Toxicity: Ingestion/Oral-Rat LD50 • 8290 mg/kg  |  |

| GHS Properties | Classification |
|----------------|----------------|
|                |                |

Preparation Date: 06/May/2015 Format: GHS Language: English (US) Revision Date: 06/May/2015

| Acute toxicity                | UN GHS • Acute Toxicity - Oral 5         |
|-------------------------------|--|
| Aspiration Hazard             | UN GHS • Classification criteria not met |
| Carcinogenicity               | UN GHS • Classification criteria not met |
| Germ Cell Mutagenicity        | UN GHS • Classification criteria not met |
| Skin corrosion/Irritation     | UN GHS • Classification criteria not met |
| Skin sensitization            | UN GHS • Classification criteria not met |
| STOT-RE                       | UN GHS • Classification criteria not met |
| STOT-SE                       | UN GHS • Classification criteria not met |
| Toxicity for Reproduction     | UN GHS • Classification criteria not met |
| Respiratory sensitization     | UN GHS • Classification criteria not met |
| Serious eye damage/Irritation | UN GHS • Classification criteria not met |

# Potential Health Effects

#### Inhalation

Acute (Immediate)

**Chronic (Delayed)** 

• Under normal conditions of use, no health effects are expected.

 Refer to the product insert and/or product prescribing information for comprehensive information regarding adverse reactions and other important symptoms and effects.

## Skin

Acute (Immediate)

**Chronic (Delayed)** 

- Not expected to cause skin irritation.
- Refer to the product insert and/or product prescribing information for comprehensive information regarding adverse reactions and other important symptoms and effects.

#### Eye

**Acute (Immediate)** 

**Chronic (Delayed)** 

- May cause eye irritation in sensitive individuals.
- Refer to the product insert and/or product prescribing information for comprehensive information regarding adverse reactions and other important symptoms and effects. Latanoprost Ophthalmic Solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes, and growth of eyelashes. Pigmentation is expected to increase as long as Latanoprost Ophthalmic Solution is administered. After discontinuation of Latanoprost Ophthalmic Solution, pigmentation of the iris is likely to be permanent while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The effects of increased pigmentation beyond 5 years are not known.

#### Ingestion

**Acute (Immediate)** 

**Chronic (Delayed)** 

- Not expected to be an exposure route. However, may cause gastric and intestinal irritation if ingested.
- Refer to the product insert and/or product prescribing information for comprehensive information regarding adverse reactions and other important symptoms and effects.

# **Section 12 - Ecological Information**

# **Toxicity**

This material has not been tested for environmental effects.

# Persistence and degradability

Substance is readily biodegradable.

# **Bioaccumulative potential**

Revision Date: 06/May/2015

No data available

Preparation Date: 06/May/2015

Format: GHS Language: English (US)
UN GHS

## Mobility in Soil

No data available

#### Other adverse effects

## Section 13 - Disposal Considerations

#### Waste treatment methods

**Product waste** 

 Waste characterizations and compliance with applicable laws are the responsibility solely of the waste generator.

Packaging waste

Dispose of content and/or container in accordance with local, regional, national, and/or international regulations.

## **Section 14 - Transport Information**

|           | UN<br>number | UN proper shipping name | Transport hazard class (es) | Packing<br>group | Environmental<br>hazards |
|-----------|--------------|-------------------------|-----------------------------|------------------|--------------------------|
| DOT       | NDA          | not regulated           | NDA                         | NDA              | NDA                      |
| TDG       | NDA          | not regulated           | NDA                         | NDA              | NDA                      |
| IMO/IMDG  | NDA          | not regulated           | NDA                         | NDA              | NDA                      |
| IATA/ICAO | NDA          | not regulated           | NDA                         | NDA              | NDA                      |

Special precautions for user

and the IBC Code

Transport in bulk according to Annex II of MARPOL 73/78

- No data available
- No data available

# Section 15 - Regulatory Information

## Safety, health and environmental regulations/legislation specific for the substance or mixture SARA Hazard Classifications • No data available

|                               | Inventory       |            |           |      |  |
|-------------------------------|-----------------|------------|-----------|------|--|
| Component                     | CAS             | Canada DSL | EU EINECS | TSCA |  |
| Latanoprost                   | 130209-82-<br>4 | No         | No        | No   |  |
| Benzalkonium<br>Chloride      | 63449-41-2      | Yes        | Yes       | Yes  |  |
| Dibasic Sodium<br>Phosphate   | 7558-80-7       | Yes        | Yes       | Yes  |  |
| Sodium chloride               | 7647-14-5       | Yes        | Yes       | Yes  |  |
| Monobasic Sodium<br>Phosphate | 10049-21-5      | No         | No        | No   |  |
| Water                         | 7732-18-5       | Yes        | Yes       | Yes  |  |

#### Canada

#### Labor

Preparation Date: 06/May/2015

Revision Date: 06/May/2015

Canada - WHMIS - Classifications of Substances

· Benzalkonium Chloride 63449-41-2

Not Listed

Format: GHS Language: English (US)

| Sodium chloride                             | 7647-14-5   | Uncontrolled product according to WHMIS classification criteria |
|---|-------------|---|
| Monobasic Sodium Phosphate                  | 10049-21-5  | Not Listed  |
|   |             | Uncontrolled product  |
| • Water                                     | 7732-18-5   | according to WHMIS  |
|   |             | classification criteria   |
| Latanoprost                                 | 130209-82-4 | Not Listed  |
|   |             | Uncontrolled product  |
| Dibasic Sodium Phosphate                    | 7558-80-7   | according to WHMIS  |
|   |             | classification criteria   |
| Canada - WHMIS - Ingredient Disclosure List |             |   |
| Benzalkonium Chloride                       | 63449-41-2  | Not Listed  |
| Sodium chloride                             | 7647-14-5   | Not Listed  |
| Monobasic Sodium Phosphate                  | 10049-21-5  | Not Listed  |
| • Water                                     | 7732-18-5   | Not Listed  |
| Latanoprost                                 | 130209-82-4 | Not Listed  |
| Dibasic Sodium Phosphate                    | 7558-80-7   | Not Listed  |
|   |             |   |

# **Europe**

| ther   |             |  |
|--|-------------|--|
| EU - CLP (1272/2008) - Annex VI - Table 3.2 - Classification | 62440 44 2  | V=, D24/22 C, D24 N, D50                   |
| Benzalkonium Chloride  | 63449-41-2  | Xn; R21/22 C; R34 N; R50                   |
| Sodium chloride  | 7647-14-5   | Not Listed                                 |
| Monobasic Sodium Phosphate                                   | 10049-21-5  | Not Listed                                 |
| • Water  | 7732-18-5   | Not Listed                                 |
| Latanoprost  | 130209-82-4 | Not Listed                                 |
| Dibasic Sodium Phosphate                                     | 7558-80-7   | Not Listed                                 |
| EU - CLP (1272/2008) - Annex VI - Table 3.2 - Labelling      |             |  |
| Benzalkonium Chloride  | 63449-41-2  | C N R:21/22-34-50 S:(2)-<br>36/37/39-45-61 |
| Sodium chloride  | 7647-14-5   | Not Listed                                 |
| Monobasic Sodium Phosphate                                   | 10049-21-5  | Not Listed                                 |
| Water  | 7732-18-5   | Not Listed                                 |
| Latanoprost  | 130209-82-4 | Not Listed                                 |
| Dibasic Sodium Phosphate                                     | 7558-80-7   | Not Listed                                 |
| EU - CLP (1272/2008) - Annex VI - Table 3.2 - Safety Phrases |             |  |
| Benzalkonium Chloride  | 63449-41-2  | S:(2)-36/37/39-45-61                       |
| Sodium chloride  | 7647-14-5   | Not Listed                                 |
| Monobasic Sodium Phosphate                                   | 10049-21-5  | Not Listed                                 |
| • Water  | 7732-18-5   | Not Listed                                 |
|  | 130209-82-4 | Not Listed                                 |
| Latanoprost  | 100200 02 4 | . 101 =10104                               |

## **United States**

| 63449-41-2 | Not Listed |
|------------|------------|
| 7647-14-5  | Not Listed |
| 10049-21-5 | Not Listed |
|            | 7647-14-5  |

Preparation Date: 06/May/2015 Revision Date: 06/May/2015

Format: GHS Language: English (US)

| Water                    | 7732-18-5   | Not Listed |  |
|--------------------------|-------------|------------|--|
| Latanoprost              | 130209-82-4 | Not Listed |  |
| Dibasic Sodium Phosphate | 7558-80-7   | Not Listed |  |
|                          |             |            |  |

#### **United States - California**

| Environment  |             |            |
|--|-------------|------------|
| U.S California - Proposition 65 - Carcinogens List               |             |            |
| Benzalkonium Chloride  | 63449-41-2  | Not Listed |
| Sodium chloride  | 7647-14-5   | Not Listed |
| Monobasic Sodium Phosphate                                       | 10049-21-5  | Not Listed |
| Water  | 7732-18-5   | Not Listed |
| Latanoprost  | 130209-82-4 | Not Listed |
| Dibasic Sodium Phosphate   | 7558-80-7   | Not Listed |
| U.S California - Proposition 65 - Developmental Toxicity         |             |            |
| Benzalkonium Chloride  | 63449-41-2  | Not Listed |
| Sodium chloride  | 7647-14-5   | Not Listed |
| Monobasic Sodium Phosphate                                       | 10049-21-5  | Not Listed |
| Water  | 7732-18-5   | Not Listed |
| Latanoprost  | 130209-82-4 | Not Listed |
| Dibasic Sodium Phosphate   | 7558-80-7   | Not Listed |
| U.S California - Proposition 65 - Reproductive Toxicity - Female |             |            |
| Benzalkonium Chloride  | 63449-41-2  | Not Listed |
| Sodium chloride  | 7647-14-5   | Not Listed |
| Monobasic Sodium Phosphate                                       | 10049-21-5  | Not Listed |
| Water  | 7732-18-5   | Not Listed |
| Latanoprost  | 130209-82-4 | Not Listed |
| Dibasic Sodium Phosphate   | 7558-80-7   | Not Listed |
| U.S California - Proposition 65 - Reproductive Toxicity - Male   |             |            |
| Benzalkonium Chloride  | 63449-41-2  | Not Listed |
| Sodium chloride  | 7647-14-5   | Not Listed |
| Monobasic Sodium Phosphate                                       | 10049-21-5  | Not Listed |
| Water  | 7732-18-5   | Not Listed |
| Latanoprost  | 130209-82-4 | Not Listed |
| Dibasic Sodium Phosphate   | 7558-80-7   | Not Listed |

## Section 16 - Other Information

# Last Revision Date Preparation Date Disclaimer/Statement of Liability

- 06/May/2015
- 06/May/2015
- To the best of our knowledge, the information contained herein is accurate. However, neither Bausch & Lomb Incorporated nor any of its subsidiaries assumes any liability whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist. NO WARRANTY, EXPRESS OR IMPLIED, OF MERCHANTABILITY, FITNESS OR OTHERWISE IS MADE. In no event shall Bausch & Lomb Incorporated or any of its subsidiaries be liable for any special, incidental or consequential damages.

Preparation Date: 06/May/2015

Revision Date: 06/May/2015 Page 9 of 10

Latanoprost Ophthalmic Solution, 0.005%

Preparation Date: 06/May/2015
Revision Date: 06/May/2015
UN GHS
UN GHS